

**Minutes of the December 14, 2012  
Pharmacy & Therapeutics (P&T) Committee Meeting  
SD Department of Social Services, Medical Services Division**

**Members present**

Debra Farver, PharmD; Timothy Soundy, MD; Bill Ladwig, RPh; Mikel Holland, MD; Kelly Oehlke, PharmD; Lenny Petrick, PharmD; Dana Darger, RPh; James Engelbrecht, MD

**Members absent**

Rick Holm, MD; Michelle Baack, MD

**DSS staff present**

Mike Jockheck, RPh; Kirby Stone, Director of Medical Services

**HID staff present**

Candace Rieth, PharmD

**Administrative Business**

The P&T meeting was called to order by D. Darger at approximately 1:00pm. The minutes of the September 14, 2012 meeting were presented. B. Ladwig made a motion to approve. D. Farver seconded the motion. The motion was approved unanimously.

**Prior Authorization Update and Statistics**

C. Rieth presented an overview of the prior authorization (PA) activity for October 2012. There were a total of 5,557 PAs processed in the month of October, with 99.8% of those requests responded to in less than 8 hours. There were 4,408 (79%) requests received electronically and 1,149 (21%) requests received by fax.

**Analysis of the Top 15 Therapeutic Classes**

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 07/01/2012 – 09/30/2012. The top five classes were antipsychotics, cerebral stimulants, amphetamines, central nervous system agents misc., and corticosteroids (respiratory tract). The top 15 therapeutic classes make up 40.35% of total claims. C. Rieth also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 12.03% of total claims. After reviewing the reports, the committee requested that ADHD and Opiates be discussed at the next meeting.

**Nasal Steroids for Allergic Rhinitis**

At the September meeting, the committee reviewed utilization for nasal steroids. A motion was made to develop a PA form and criteria for the nasal steroids used to treat allergic rhinitis. C. Rieth reviewed the prior authorization form. A motion was made by B. Ladwig to approve the PA form. J. Engelbrecht seconded the motion. L. McDermott, representing Sunovion, spoke regarding Zetonna. The motion was approved.

**Antiretrovirals Review**

C. Rieth reviewed utilization and trend summary information for the antiretrovirals. This topic was tabled.

**Genitourinary Smooth Muscle Relaxants Review**

C. Rieth reviewed genitourinary smooth muscle relaxant (GSM) clinical information and utilization including the age distribution of recipients. A motion was made by J. Engelbrecht to develop a prior authorization form and criteria for GSMs. T. Soundy seconded the motion. T. Ahlers, representing Pfizer, spoke regarding Toviaz. The motion was approved.

### **Rayos Review**

C. Rieth reviewed Rayos clinical information. A motion was made by B. Ladwig to place Rayos on prior authorization. J. Engelbrecht seconded the motion. There was no public comment. The motion was approved.

### **Xeljanz Review**

C. Rieth reviewed Xeljanz clinical information. A motion was made by J. Engelbrecht to develop a prior authorization and criteria for Xeljanz. K. Oehlke seconded the motion. V. Castellano, representing Pfizer, spoke regarding Xeljanz. The motion was approved.

### **Aubagio Review**

C. Rieth reviewed Aubagio clinical information. A motion was made by B. Ladwig to place Aubagio on prior authorization. K. Oehlke seconded the motion. There was no public comment. The motion was approved.

### **Truvada for pre-exposure HIV prophylaxis**

C. Rieth reviewed Truvada clinical information. D. Darger suggested that he could consult with HIV experts regarding the importance of managing Truvada. This information will be reviewed at a future meeting.

### **Xifaxan Review**

C. Rieth reviewed Xifaxan clinical information. A motion was made by D. Farver to place Xifaxan on prior authorization. T. Soundy seconded the motion. There was no public comment. The motion was approved.

### **Relistor Review**

C. Rieth reviewed Relistor clinical information. A motion was made by B. Ladwig to place Relistor on prior authorization. D. Farver seconded the motion. There was no public comment. The motion was approved.

The next meeting date is scheduled for March 8, 2013. A motion was made by B. Ladwig to adjourn the SD Medicaid P&T meeting. D. Farver seconded the motion. Motion passed unanimously and the meeting was adjourned.